A point-to-point response to the Reviewers comments:

Reviewer #1:
We very much appreciate the comments of the Reviewer and in agreement with his suggestion, added two figures to the paper. The first figure includes a schematic model showing the potential effects of PICOT interaction with EED on the PRC2 target gene transcriptional machinery, and the second figure demonstrates the survival probability of cancer patients which express high or low levels of *PICOT* or *CCND2* mRNA.

Reviewer #2:
We thank the Reviewer for the constructive comments and in agreement with his suggestions performed the following corrections.
1. Title: We agree that a title emphasizing the clinical role of PICOT in cancer would have been more attractive to the readers. However, such a title might be more speculative by nature, since at present, the potential link of PICOT to cancer formation is based on statistical data and the mechanism by which PICOT promote cell transformation or affect tumor cell growth is unclear. We think that for the integrity of this manuscript and the good reputation of World Journal of Immunology, usage of the current title, which is based on solid data obtained by experimental work performed on lymphocytes, is the preferable choice.
2. Abstract: The Reviewer commented that: "Some editing needed on the brackets (line 2)". It relates to the sentence: "The mammalian protein kinase C (PKC)-interacting cousin of thioredoxin (PICOT; also termed glutaredoxin 3 (Grx3; Glrx3)) is a multi-domain mono-thiol glutaredoxin". In line 2, there are two left side brackets and two right side brackets. Thus, the number of left and right side brackets is even. In the abbreviated names of "glutaredoxin 3" there are two different terms, "Grx3" and "Glrx3". This is not a mistake. Both abbreviations represent "glutaredoxin" and are in use in the scientific literature: "Grx" is mentioned in 551 PubMed cited manuscripts, while "Glrx" is mentioned in 187 PubMed cited manuscripts.
3. Illustrations: In agreement with the Reviewer's suggestions, we added two figures to the paper. The first figure includes a schematic model showing the potential effects of PICOT interaction with EED on the PRC2 target gene transcriptional machinery, and the second figure demonstrates the survival probability of cancer patients which express high or low levels of *PICOT* or *CCND2* mRNA.
4. Discussion: In agreement with the Reviewer's comment, additional discussions were added to the text to emphasize the potential clinical aspects of the new findings on PICOT and CCND2 (see pages 6 and 9).
5. "Therefore" two times in page 7 line 19: We thank the Reviewer for pointing out this error. The sentence was corrected by omitting the second "therefore" word.

***Science Editor*:**
1. 'Author contributions' was added to the 1st page of this manuscript.
2. Copies of grant application approval letters from the BSF, ISF and ICRF were provided.
3. A "core tip" section was added immediately after the key words.

***Editorial Office Director*:**
1. 'Author contributions' was added to the 1st page of this manuscript.
2. A "core tip" section was added immediately after the key words.
3. Copies of grant application approval letters from the BSF, ISF and ICRF were provided.